Understanding breast cancer stem cell heterogeneity: Time to move on to a new research paradigm

BMC Medicine

Volumn 11, Issue 1, 2013, Pages

  Mannello, Ferdinando ^a  

^a UNIVERSITY OF URBINO   (Italy)

Author keywords

Biomarkers; Breast cancer; Cancer heterogeneity; CD44 CD24 CD49f; Ep CAM; Mammosphere; Stem cells

Indexed keywords

ALPHA6 INTEGRIN; BIOLOGICAL MARKER; CD24 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN;

APTITUDE; BIOLOGY; BREAST CANCER; BREAST CANCER STEM CELL; CANCER STEM CELL; CELL HETEROGENEITY; CELL SUBPOPULATION; CLINICAL PRACTICE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MICROENVIRONMENT; NEOPLASM; NOTE; PHENOTYPE; RESEARCH; SINGLE CELL ANALYSIS;

ANIMALS; BIOMEDICAL RESEARCH; BREAST NEOPLASMS; CELL LINE, TUMOR; COMPREHENSION; FEMALE; GENETIC HETEROGENEITY; HUMANS; NEOPLASTIC STEM CELLS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880335966     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-11-169     Document Type: Note

References (23)

1. Hsiao YH, Chou MC, Fowler C, Mason JT, Man YG. Breast cancer heterogeneity: mechanisms, proofs, and implications. J Cancer 2010, 1:6-13. 2931354, 20842218.
2. Dawson SJ, Rueda OM, Aparicio S, Caldas C. A new genome-driven integrated classification of breast cancer and its implications. EMBO J 2013, 32:617-628. 10.1038/emboj.2013.19, 23395906.
3. Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol 2013, 8:277-302. 10.1146/annurev-pathol-020712-163923, 23092187.
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30. 10.3322/caac.21166, 23335087.
5. Polyak K. Heterogeneity in breast cancer. J Clin Invest 2011, 121:3786-3788. 10.1172/JCI60534, 3195489, 21965334.
6. Place AE, Jin HS, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res 2011, 13:227. 10.1186/bcr2912, 3326543, 22078026.
7. Mannello F, Medda V, Tonti GA. Protein profile analysis of the breast microenvironment to differentiate healthy women from breast cancer patients. Expert Rev Proteomics 2009, 6:43-60. 10.1586/14789450.6.1.43, 19210126.
8. Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest 2011, 121:3797-3803. 10.1172/JCI57152, 3195649, 21965336.
9. Gangopadhyay S, Nandy A, Hor P, Mukhopadhyay A. Breast cancer stem cells: a novel therapeutic target. Clin Breast Cancer 2013, 13:7-15. 10.1016/j.clbc.2012.09.017, 23127340.
10. Ablett MP, Singh JK, Clarke RB. Stem cells in breast tumours: are they ready for the clinic?. Eur J Cancer 2012, 48:2104-2116. 10.1016/j.ejca.2012.03.019, 22542086.
11. Valent P, Bonnet D, Wohrer S, Andreeff M, Copland M, Chomienne C, Eaves C. Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications. Cancer Res 2013, 73:1037-1045. 10.1158/0008-5472.CAN-12-3678, 23345162.
12. Polyak K, Vogt PK. Progress in breast cancer research. Proc Natl Acad Sci USA 2012, 109:2715-2717. 10.1073/pnas.1201091109, 3286956, 22331869.
13. Virchow R. Die cellular pathologie in ihrer begründung auf physiologische und pathologische gewebelehre 1858, Berlin: Von August Hirschwald.
14. Nowell PC. The clonal evolution of tumor cell populations. Science 1976, 194:23-28. 10.1126/science.959840, 959840.
15. Li Y, Laterra J. Cancer stem cells: distinct entities or dynamically regulated phenotypes?. Cancer Res 2012, 72:576-580. 10.1158/0008-5472.CAN-11-3070, 3271803, 22298594.
16. Vermeulen L, de Sousa EM, Richel DJ, Medema JP. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol 2012, 13:e83-e89. 10.1016/S1470-2045(11)70257-1, 22300863.
17. Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012, 22:457-472. 10.1038/cr.2012.13, 3292302, 22357481.
18. Medema JP. Cancer stem cells: the challenges ahead. Nat Cell Biol 2013, 15:338-344. 10.1038/ncb2717, 23548926.
19. Al-Hajj M, Wicha MS, Ito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
20. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567. 10.1016/j.stem.2007.08.014, 2423808, 18371393.
21. Ghebeh H, et al. Profiling of normal and malignant breast tissues show CD44high/CD24low phenotype as a predominant stem/progenitor marker when used in combination with Ep-CAM/CD49f markers. BMC Cancer 2013, 13:289. 10.1186/1471-2407-13-289, 3702414, 23768049.
22. Valent P, Bonnet D, De MR, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012, 12:767-775. 10.1038/nrc3368, 23051844.
23. Mannello F, Ligi D, Magnani M. Deciphering the single-cell omic: innovative application for translational medicine. Expert Rev Proteomics 2012, 9:635-648. 10.1586/epr.12.61, 23256674.